Hindle Research Group
Our pharmaceutical aerosol development laboratories are located on the MCV campus of Virginia Commonwealth University. This interdisciplinary group works in collaboration with Dr Worth Longest (Department of Mechanical Engineering) to combine computational fluid dynamics (CFD) and design engineering to produce novel pharmaceutical aerosol drug delivery systems. Current projects are developing a high efficiency handheld dry powder inhaler and devices for improving aerosol delivery during non-invasive ventilation using controlled condensation growth methods.
Our groups have also focused on the development of innovative in silico and in vitro methods to assess the pulmonary deposition from commercial inhalers using realistic oropharyngeal models. Other projects are investigating nanoparticle formation techniques for inhalation and nasal drug delivery and the delivery of antibiotics by inhalation.
Our group has received funding from the National Institutes of Health, the Food and Drug Administration, the Bill and Melinda Gates Foundation and the Pharmaceutical Industry.
Some of our currently funded projects are :
• Development of Synthetic Lung Surfactant Formulations and Delivery Devices for Treating Infants with RDS in Low Resource Environments (Bill and Melinda Gates Foundation)
• Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support (NIH/NHLBI).
• Developing high efficiency dry powder inhalers for the delivery of tobramycin to pediatric cystic fibrosis patients (NIH/NICHD).